Management of Elevated PTH with eGFR 57 and Normal Serum Calcium

Pathophysiology and Diagnosis

Normal serum calcium with elevated PTH in Stage 3 CKD represents an inappropriate hormonal response, as normal 1,25(OH)₂D₃ levels fail to properly suppress PTH synthesis in the parathyroid glands 1
Bone biopsies in such patients often show histomorphometric features of hyperparathyroid bone disease despite only modest PTH elevations 1

For patients with elevated PTH, eGFR 57 ml/min/1.73m², and normal serum calcium, the American Journal of Kidney Diseases recommends low-dose active vitamin D therapy as the first-line treatment to reduce PTH levels and improve bone health 1, 2
If 25(OH) vitamin D <30 ng/mL: Correct vitamin D deficiency first, according to the American Journal of Kidney Diseases 3
If 25(OH) vitamin D ≥30 ng/mL and serum phosphorus <4.6 mg/dL: Start active vitamin D therapy, with calcitriol 0.25 μg/day or alfacalcidol 0.25-0.5 μg/day, as recommended by the American Journal of Kidney Diseases 1, 3

Check serum calcium and phosphorus monthly for first 3 months, then every 3 months, as recommended by the American Journal of Kidney Diseases 2
Measure PTH levels every 3 months for 6 months, then every 3 months thereafter, according to the American Journal of Kidney Diseases 2
Target PTH range should be appropriate for CKD stage, as recommended by the American Journal of Kidney Diseases 5
If PTH falls below target range: Hold vitamin D therapy until PTH rises above target, then resume at half the previous dose, as recommended by the American Journal of Kidney Diseases 2
If serum calcium exceeds 9.5 mg/dL: Hold vitamin D therapy until calcium normalizes, then resume at half the previous dose, according to the American Journal of Kidney Diseases 2

Controlled trials in Stage 3 CKD patients show that low-dose active vitamin D therapy effectively lowers PTH levels, improves bone histology, and increases bone mineral density, as reported by the American Journal of Kidney Diseases 1
Early intervention with active vitamin D when creatinine clearance exceeds 30 mL/min/1.73m² results in better bone histology outcomes when patients eventually reach Stage 5 CKD, according to the American Journal of Kidney Diseases 1
With proper dosing and monitoring, these benefits occur without worsening kidney function, as recommended by the American Journal of Kidney Diseases 1

Do not attempt to normalize PTH to the range for patients without CKD, as this may lead to adynamic bone disease, as warned by the American Journal of Kidney Diseases 5
Avoid hypercalcemia and hyperphosphatemia, which can increase risk of vascular calcification, as reported by the American Journal of Kidney Diseases 4
Recognize that "intact PTH" assays may detect biologically inactive fragments, potentially leading to overestimation of true PTH activity, as noted by the American Journal of Kidney Diseases 5